CSL (OTCMKTS:CSLLY) Shares Gap Down – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped down prior to trading on Tuesday . The stock had previously closed at $54.02, but opened at $51.08. CSL shares last traded at $51.28, with a volume of 3,160 shares trading hands.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

CSL Trading Down 0.0%

The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. The stock’s fifty day simple moving average is $58.52 and its 200-day simple moving average is $63.35.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.